Showing 7171-7180 of 10738 results for "".
Physicians Have a Duty to Disobey
https://practicaldermatology.com/topics/practice-management/physicians-have-a-duty-to-disobey/24208/When I was in high school in the 1970s, we were required to read Henry David Thoreau’s essay, Civil Disobedience. We were taught that when confronted with something clearly wrong or unethical, it is our duty to stand up against it—even if it means not abiding by unjust laws or rules. We were to liveBiosimilar Medicines in Dermatology: Key Aspects
https://practicaldermatology.com/topics/psoriasis/biosimilar-medicines-in-dermatology-key-aspects/22929/After the recent enactment of a specific approval pathway for biosimilars and publication of the first draft guidelines on biosimilar product development by the FDA, biosimilars are expected to be available in the US soon.DermWireTV: Qwo Approved, Assessing Resident Anxiety
https://practicaldermatology.com/videos/dermwire-tv/dermwiretv-qwo-approved-assessing-resident-anxiety/19830/FDA has approved Qwo (collagenase clostridium histolyticum-aaes) from Endo, the first injectable treatment approved for moderate to severe cellulite in the buttocks of adult women. A recent survey offers perspective on anxiety among third-year dermatology residents in light of the COVID crisis. AlleDermWire TV: Merz Reorganizes; Amzeeq Approved; Restoration Merges with Venus Concept
https://practicaldermatology.com/videos/dermwire-tv/dermwire-tv-merz-reorganizes-amzeeq-approved-restoration-merges-with-venus-concept/19694/Bob Rhatigan, newly appointed Global Chief Executive Officer of Merz Aesthetics, speaks about Merz reorganization. Amzeeq topical foam (Foamix Pharmaceuticals) approved for inflammatory, non-nodular, moderate to severe acne vulgaris in adults and pediatric patients 9 years of age and older. FDCombination Biologic and GLP-1 Receptor Agonist Therapy in Psoriasis
https://practicaldermatology.com/topics/psoriasis/combination-biologic-and-glp-1-receptor-agonist-therapy-in-psoriasis/60858/New evidence indicates benefits of a dual-treatment strategy for many patients.Effectiveness of Early Moisturizer Use in Atopic Dermatitis Prevention
https://practicaldermatology.com/issues/novemberdecember-2025/effectiveness-of-early-moisturizer-use-in-atopic-dermatitis-prevention/48889/In the 2025 study by Simpson et al entitled “Emollients to Prevent Pediatric Eczema: A Randomized Clinical Trial,” once-daily, full-body emollient use initiated at 9 weeks of age significantly reduced the cumulative incidence of atopic dermatitis (AD) by 24 months.The Importance of Diversity in Clinical Trials
https://practicaldermatology.com/issues/april-2025/the-importance-of-diversity-in-clinical-trials/35606/The disproportionate representation of certain segments of the population in clinical trials is no secret, and research has shown that psoriasis studies are the least racially diverse of all dermatology studies in the US.Pulse’s CellFX for Dermatologic Applications
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/pulses-cellfx-for-dermatologic-applications/23464/A novel technology targets cells to treat warts, sebaceuous hyperplasia, and more.Currents: Updates and Innovations
https://practicaldermatology.com/programs/practical-dermatology/currents-updates-and-innovations/23832/The World Health Organization (WHO) will begin using “mpox” as a synonym for monkeypox. Both names will be used simultaneously for 1 year while “monkeypox” is phased out.Acute Contact Urticaria Due To Use of Cocamidopropyl Betaine-Containing Products Confirmed with Patch Testing
https://practicaldermatology.com/topics/other-dermatology/acute-contact-urticaria-due-to-use-of-cocamidopropyl-betaine-containing-products-confirmed-with-patch-testing/24218/A 23-year-old Caucasian woman presented with progressive worsening recurrent symptoms of hives, burning sensation, and pruritus located on the skin of the face, neck, and arms (see Fig 1, Fig 2). These symptoms began following the use of Biolage Matrix shampoo. She started taking antihistamines (lor